AtriCure, Inc. Q1 2011 Financial Summary
Business Context and Reporting Period
This summary covers the quarterly period ended March 31, 2011, for AtriCure, Inc., a medical device company specializing in surgical ablation systems for cardiac tissue and left atrial appendage exclusion devices. The company operates as a single segment with sales in the United States and internationally.
Key Financial Metrics
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenue | $15,637,081 | $13,951,800 |
| Gross Profit | $11,892,804 | $10,679,164 |
| Gross Margin | 76.1% | 76.5% |
| Net Loss | $(1,273,046) | $(2,009,351) |
| Loss Per Share (Basic/Diluted) | $(0.08) | $(0.13) |
| Cash and Cash Equivalents | $7,685,746 | $4,230,709 (Dec 31, 2010) |
| Short-Term Investments | $7,973,664 | $8,340,028 (Dec 31, 2010) |
| Total Debt (Current + Long-Term) | $7,586,902 | $2,888,889 (Dec 31, 2010) |
| Working Capital | $22,421,112 | $17,613,128 (Dec 31, 2010) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 12.1% year-over-year. U.S. sales rose 9.7% driven by the new AtriClip system, while international sales grew 21.1% due to new product introductions and direct market expansion in Europe and Asia.
- Profitability Improvement: Net loss narrowed by 36.6% to $1.27 million. Operating loss decreased from $1.69 million to $1.07 million.
- Debt Restructuring: In March 2011, the company secured a new $7.5 million term loan to refinance existing debt, extending the maturity date and reducing the interest rate to a fixed 6.75%. This resulted in a significant increase in total debt outstanding compared to the prior year-end.
- Cash Flow: Net cash used in operating activities improved significantly to $0.87 million (from $2.98 million used in Q1 2010). Financing activities provided $4.33 million, primarily from the new term loan proceeds.
Outlook, Risks, and Management Commentary
- Regulatory Status: The company received a major deficiency letter from the FDA regarding its PMA for the ABLATE system in March 2011. Additionally, the FDA issued a Form 483 regarding manufacturing deficiencies. The company is working to resolve these items.
- Clinical Trials: The DEEP AF feasibility trial is ongoing with 11 patients enrolled as of the filing date. The trial was modified to include the AtriClip system.
- Legal Contingencies:
- DOJ Settlement: A tentative settlement with the Department of Justice regarding False Claims Act violations was finalized in February 2010. A liability of $2.78 million remains, with $0.53 million classified as current.
- Class Action: A securities class action lawsuit was settled for $2.0 million, with the company expecting full recovery via insurance.
- Liquidity: Management believes current cash, investments, and the $7.7 million available under the revolving credit facility are sufficient to meet needs for the next 12 months.
Investor Verification Checklist
- Verify the status of the FDA PMA deficiency letter and the Form 483 manufacturing inspection findings.
- Confirm the timeline for the resolution of the DOJ settlement payments and the Corporate Integrity Agreement requirements.
- Monitor the enrollment progress and results of the DEEP AF clinical trial.
- Review the impact of the new AtriClip system on gross margins, as it currently carries a lower margin than disposable ablation products.
- Assess the company's ability to meet minimum purchase requirements for the MicroPace ORLab to retain exclusive distribution rights.